This is a preview of subscription content, log in via an institution to check access.
Notes
The study was financially supported by Merck KGaA.
Reference
Xue W, et al. A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany. International Journal of Women's Health : 13 May 2019. Available from: URL: https://doi.org/10.2147/IJWH.S193048
Rights and permissions
About this article
Cite this article
Are lower-cost follitropin-alfa biosimilars good value for money?. PharmacoEcon Outcomes News 829, 3 (2019). https://doi.org/10.1007/s40274-019-5917-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5917-3